Hypermarcas (OTCMKTS:HYPMY) Sees Large Volume Increase – Still a Buy?

Shares of Hypermarcas (OTCMKTS:HYPMY – Get Free Report) saw strong trading volume on Monday . Approximately 53,617 shares traded hands during trading, an increase of 170% from the previous session’s volume of 19,840 shares.The stock last traded at $4.56 and had previously closed at $4.5050.

Analyst Ratings Changes

Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy”.

Get Hypermarcas alerts:

Read Our Latest Stock Report on HYPMY

Hypermarcas Trading Up 3.1%

The company has a quick ratio of 1.26, a current ratio of 1.86 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $3.27 billion, a P/E ratio of 9.29 and a beta of 0.71. The business has a fifty day moving average price of $4.22 and a 200 day moving average price of $4.29.

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, analysts expect that Hypermarcas will post 0.53 earnings per share for the current fiscal year.

Hypermarcas Company Profile

(Get Free Report)

Hypermarcas SA was a Brazilian consumer health and pharmaceutical company that developed, manufactured and marketed branded products for healthcare, personal care and consumer markets. Its portfolio historically included over-the-counter medicines, prescription products, vitamins, toiletries, cosmetics and other household or personal-care brands.

The company expanded through acquisitions and operated primarily in Brazil, building a broad portfolio of locally recognized brands. In the mid-2010s, Hypermarcas began divesting its non-pharmaceutical businesses to concentrate on healthcare and medicines.

See Also

• Five stocks we like better than Hypermarcas
• Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
• Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
• AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
• Insiders Signal Deep Value In DICK’s Sporting Goods

Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.